Betty Roosihermiatie
Pusat Humaniora, Kebijakan Kesehatan dan Pemberdayaan Masyarakat, Badan Litbang Kesehatan, Kemenkes RI, Jl. Indrapura 17 Surabaya,

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Analisis Biaya Obat Unit Rawat Jalan pada Rumah Sakit Badan Layanan Umum (BLU)/ Badan Layanan Umum Daerah (BLUD) di Indonesia Suharmiati, Suharmiati; Handayani, Lestari; Roosihermiatie, Betty
Jurnal Kefarmasian Indonesia VOLUME 9, NOMOR 2, AGUSTUS 2019
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v9i2.1369

Abstract

Drugs expenditure is the highest proportion in health services budget. financing for health services in National Universal Health Coverage era is carried out by BPJS payed to referral health facilities namely hospitals. The medicine cost at public service agency/District or Province public service agency is unknown certaintly. This descriptive study was advanced analyzes of the secondary data of 84 hospitals from health financing research in the year of 2016. The result showed that there were problems of drug availability in class B 94,6%, C 78,9% and A 77,8%. The highest proportion of generic drugs cost to total drug cost is class C hospital, followed by B class and A class hospitals i.e 40,57%, 37,83% dan 23,74% respectively. The cost of non generic drug compared to generic drugs at A, B and C class is 2,22 times, 1,15 times and 0,86 times respectively. The highest cost of generic drug is in outpatient specialist services in all class of hospitals. The cost of the drugs was increasing higher as well as the hospital class. Conclusion: The non generic drugs cost dominated in A and B class hospital while C class was generic drug cost. Generic drug use policy should be socialyzed by government and to be considered by management in order to be able to carried out cost efficiency.
Utilizing Rapid Molecular Tests (RMT/RIF) in Tuberculosis Drug-Sensitive/Resistant Discovery in Indonesia: A Pilot Study Herawati, Maria Holly; Dasuki, Dasuki; Lolong, Dina Bisara; Widiyanti, Mirna; Roosihermiatie, Betty; Permata, Ria Yuda; Raflizar, Raflizar; Ahmadi, Ferry; Supratikta, Hadi; Veruswati, Meita
Kesmas Vol. 18, No. 5
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The underdiagnosis and underreporting of tuberculosis (TB) indicators are unresolved problems. The rapid molecular test (RMT) is one of the breakthroughs for TB case finding by using safer and more sensitive equipment; it is even believed to help find drug-resistant TB. The results of several webinars held regularly by a TB program as well as its evaluation and the use of RMT formed the basis of this study. This initial pilot study aimed to provide an overview of case finding for both drug-sensitive and drug-resistant TB using RMT. A cross-sectional study was conducted on samples in several provinces in Indonesia that have used RMT, both in remote or non-remote island borders areas and fiscal capacity. Regarding the use of RMT for drug-sensitive TB case finding, the largest contributors were males aged above 15 years, while in the drug-resistant TB case finding group, the biggest contributor was the use of RMT in 2017 and 2018. Overall, the findings could only describe the situation in the study area. The use of RMT in drug-sensitive TB case finding would be maximized if the detected cases are males aged above 15 years, while RMT can help find cases of drug-resistant TB.